Mariana Vélez Pintado

Mariana Vélez Pintado

Auto-generated profile, based on publicly available information

Mariana Vélez Pintado

Clínica Especializada Condesa, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in Medical Mycology
Verified
Journal Article
Open access
PDF file
MPMariana Vélez Pintado
Mariana Vélez Pintado
ACAntonio Camiro-Zúñiga
Antonio Camiro-Zúñiga
MSMercedes Aguilar Soto
Mercedes Aguilar Soto
DCDalia Cuenca
Dalia Cuenca
MMMoises Mercado
Moises Mercado
TGthe ARMII study gruop
the ARMII study gruop
Invasive pulmonary aspergillosis (IPA) is a severe infection caused by aspergillus sp. that usually develops in patients with severe immunosuppression. IPA has been recently described in critically ill COVID-19 patients (termed as COVID-associated pulmonary aspergillosis, or CAPA) that are otherwise immunocompetent. In order to describe the characteristics of patients with CAPA, we conducted a retrospective cohort study in a tertiary care center in Mexico City. We included all patients with confirmed COVID-19 admitted to the intensive care unit that had serum or bronchoalveolar lavage galactomannan measurements. We used the criteria proposed by Koehler et al. to establish the diagnosis of CAPA. Main outcomes were the need for invasive mechanical ventilation (IMV) and in-hospital mortality. Out of a total of 83 hospitalized patients with COVID-19 in the ICU, 16 (19.3%) met the criteria for CAPA. All patients diagnosed with CAPA required IMV whereas only 84% of the patients in the non-IPA group needed this intervention (P = 0.09). In the IPA group, 31% (n = 5) of the patients died, compared to 13% (n = 9) in the non-CAPA group (P = 0.08). We conclude that CAPA is a frequent co-infection in critically ill COVID-19 patients and is associated with a high mortality rate. The timely diagnosis and treatment of IPA in these patients is likely to improve their outcome. We studied the characteristics of patients with COVID-19-associated invasive pulmonary aspergillosis (CAPA). Patients with CAPA tended to need invasive mechanical ventilation more frequently and to have a higher mortality rate. Adequate resources for its management can improve their outcome

12 April 2021 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MCMaria Fernanda Coss-Rovirosa
Maria Fernanda Coss-Rovirosa
MAMercedes Aguilar-Soto
Mercedes Aguilar-Soto
DCDalia Cuenca
Dalia Cuenca
MVMariana Velez-Pintado
Mariana Velez-Pintado
ACAntonio Camiro-Zúñiga
Antonio Camiro-Zúñiga
MMMoises Mercado
Moises Mercado
Objective: Describe the demographic, clinical, and biochemical characteristics of overweight or obese people with severe COVID-19 pneumonia and evaluate its association with mechanical ventilation requirements in a Mexican cohort. Subjects and methods: Data were obtained from medical electronic records. Patients were divided in three groups according to the World Health Organization (WHO) classification of body mass index (BMI): lean, overweight and obese. Baseline characteristics and clinical course were compared among these 3 groups. Results: The study included a total of 355 patients with confirmed COVID-19 diagnoses. Patients with obesity and overweigh, according to the WHO classification, had no significantly increased risk of requiring intubation and invasive mechanical ventilation (IMV) compared to lean subjects, with an odds ratio (OR) of 1.82 (95% CI, 0.94-3.53). A post hoc and multivariate analysis using a BMI > 35 kg/m2 to define obesity revealed that subjects above this cut off had as significantly increased risk of requiring IMV after with an OR of 2.86 (95% CI, 1.09-7.05). Conclusion: We found no higher risk of requiring IMV in patients with overweight or obesity while using conventional BMI cutoffs. According to our sensitivity analyses, the risk of IMV increases in patients with a BMI over 35 kg/m2.

1 April 2026 in Our Dermatology Online
Verified
Journal Article
Open access
AGAlejandra García
Alejandra García
MPMariana Vélez Pintado
Mariana Vélez Pintado
ASAna Paula Landeta Sa
Ana Paula Landeta Sa
KMKaren Marañón
Karen Marañón
IBIngeborg Becker
Ingeborg Becker
ABAlexandro Bonifaz
Alexandro Bonifaz
Mucocutaneous leishmaniasis: A clinical case report and literature review of health implications for human migration

14 October 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KMKaren Aranza Marañón-Solorio
Karen Aranza Marañón-Solorio
MVMariana Vélez-Pintado
Mariana Vélez-Pintado
AMAmérica Sarahí Martínez-Frías
América Sarahí Martínez-Frías
EREsmeralda Román-Mar
Esmeralda Román-Mar
MFMitzi Zaira Fong-Ponce
Mitzi Zaira Fong-Ponce
MGMARIA GONZALEZ-LARA
MARIA GONZALEZ-LARA
Filler-related complications (FRC) arise from the injection of high-density substances used to modify the body in order to harmonize gender identity and/or gender expression and represent an emerging public health problem. Among transgender women, limited access to gender-affirming healthcare, together with other psychosocial, structural, and social factors, may contribute to the use of body modification practices intended to harmonize gender identity and gender expression, including the use of injectable materials. We conducted a retrospective analytical study among transgender women with a history of filler injections receiving care at three public referral centers in Mexico City between September 2024 and July 2025. Participants were identified through review of available clinical records and transgender care registries. Transgender identity was determined based on self-identified gender documented in the clinical record and confirmed through clinical chart review. Demographic, clinical, and social variables were collected to characterize FRC and associated factors. FRC were defined as documented inflammatory, infectious, migratory, or mixed manifestations temporally associated with prior filler exposure and attributed by the treating clinical team to filler injections. A total of 222 transgender women were included, with a median age of 45 years (IQR 38–52). Overall, 99 participants (44.5%) were classified as having FRC, most commonly inflammatory or mixed presentations. Materials referred to as “biopolymers” were the most frequently reported injected substances, followed by injectable oils, and among participants with available information, 93% of injections were performed by non-medical personnel. The time between filler injection and symptom onset exceeded 5 years in 54% of participants with FRC. More than one-third of affected participants required hospitalization attributable to FRC. Nearly half of transgender women with prior filler injections experienced complications, underscoring the substantial morbidity associated with filler injections performed outside supervised medical care. These findings highlight the multifactorial structural and social context surrounding non-medically supervised filler use, including barriers to gender-affirming healthcare, and the need for multidisciplinary care pathways for FRC. Because this retrospective study was conducted at referral centers, severe complications may be overrepresented.

26 February 2026 in American Journal of Infection Control
Verified
Journal Article
Closed access
RVRodrigo Villaseñor-Echavarri
Rodrigo Villaseñor-Echavarri
MVMariana Velez-Pintado
Mariana Velez-Pintado